304 related articles for article (PubMed ID: 35169084)
21. Targeted therapy with anlotinib for a H3K27M mutation diffuse midline glioma patient with PDGFR-α mutation: a case report.
Wang Q; Niu W; Pan H
Acta Neurochir (Wien); 2022 Aug; 164(8):2063-2066. PubMed ID: 34812950
[TBL] [Abstract][Full Text] [Related]
22. Deep Learning for Noninvasive Assessment of H3 K27M Mutation Status in Diffuse Midline Gliomas Using MR Imaging.
Li J; Zhang P; Qu L; Sun T; Duan Y; Wu M; Weng J; Li Z; Gong X; Liu X; Wang Y; Jia W; Su X; Yue Q; Li J; Zhang Z; Barkhof F; Huang RY; Chang K; Sair H; Ye C; Zhang L; Zhuo Z; Liu Y
J Magn Reson Imaging; 2023 Sep; 58(3):850-861. PubMed ID: 36692205
[TBL] [Abstract][Full Text] [Related]
23. A case report of adult cerebellar high-grade glioma with H3.1 K27M mutation: a rare example of an H3 K27M mutant cerebellar tumor.
Funata N; Nobusawa S; Nakata S; Yamazaki T; Takabagake K; Koike T; Maegawa T; Yamada R; Shinoura N; Mine Y
Brain Tumor Pathol; 2018 Jan; 35(1):29-35. PubMed ID: 29264735
[TBL] [Abstract][Full Text] [Related]
24. [Clinicopathological characteristics and prognosis of diffuse midline gliomas with histone H3K27M mutation: an analysis of 30 cases].
Li HN; Shan CG; Fan CZ; Cheng LN; Wu SG; Liu MT; Jiang GY; Li Z
Zhonghua Bing Li Xue Za Zhi; 2019 Mar; 48(3):192-198. PubMed ID: 30831644
[No Abstract] [Full Text] [Related]
25. Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort.
Odia Y; Hall MD; Cloughesy TF; Wen PY; Arrillaga-Romany I; Daghistani D; Mehta MP; Tarapore RS; Ramage SC; Allen JE
Neuro Oncol; 2024 May; 26(Supplement_2):S165-S172. PubMed ID: 38386699
[TBL] [Abstract][Full Text] [Related]
26. Pharmaco-proteogenomic profiling of pediatric diffuse midline glioma to inform future treatment strategies.
Findlay IJ; De Iuliis GN; Duchatel RJ; Jackson ER; Vitanza NA; Cain JE; Waszak SM; Dun MD
Oncogene; 2022 Jan; 41(4):461-475. PubMed ID: 34759345
[TBL] [Abstract][Full Text] [Related]
27. H3 K27M-mutant diffuse midline gliomas in different anatomical locations.
Wang L; Li Z; Zhang M; Piao Y; Chen L; Liang H; Wei Y; Hu Z; Zhao L; Teng L; Lu D
Hum Pathol; 2018 Aug; 78():89-96. PubMed ID: 29727696
[TBL] [Abstract][Full Text] [Related]
28. H3 K27M-mutant diffuse midline glioma with osseous metastases: A case report and a literature review.
Al Sharie S; Talafha M; Abu Laban D; Al Awabdeh T; Al-Mousa A; Al-Masri N; Al-Hussaini M
Clin Neuropathol; 2022; 41(6):263-270. PubMed ID: 35770519
[TBL] [Abstract][Full Text] [Related]
29. Detecting the H3F3A mutant allele found in high-grade pediatric glioma by real-time PCR.
Zhang R; Han J; Daniels D; Huang H; Zhang Z
J Neurooncol; 2016 Jan; 126(1):27-36. PubMed ID: 26376656
[TBL] [Abstract][Full Text] [Related]
30. Oncohistones and disrupted development in pediatric-type diffuse high-grade glioma.
Ocasio JK; Budd KM; Roach JT; Andrews JM; Baker SJ
Cancer Metastasis Rev; 2023 Jun; 42(2):367-388. PubMed ID: 37119408
[TBL] [Abstract][Full Text] [Related]
31. Diffuse midline glioma with H3 K27M-mutation in an 83-year-old woman.
Low JT; Wang SH; B Peters K
CNS Oncol; 2021 Jun; 10(2):CNS71. PubMed ID: 33908265
[TBL] [Abstract][Full Text] [Related]
32. Spinal Cord Diffuse Midline Gliomas With H3 K27m-Mutant: Clinicopathological Features and Prognosis.
Wang YZ; Zhang YW; Liu WH; Chai RC; Cao R; Wang B; An SY; Jiang WJ; Xu YL; Yang J; Jia WQ
Neurosurgery; 2021 Jul; 89(2):300-307. PubMed ID: 34015818
[TBL] [Abstract][Full Text] [Related]
33. The prognostic significance of HIST1H3B/C and H3F3A K27M mutations in diffuse midline gliomas is influenced by patient age.
Vuong HG; Ngo TNM; Le HT; Dunn IF
J Neurooncol; 2022 Jul; 158(3):405-412. PubMed ID: 35606633
[TBL] [Abstract][Full Text] [Related]
34. Optimal therapeutic targeting by HDAC inhibition in biopsy-derived treatment-naïve diffuse midline glioma models.
Vitanza NA; Biery MC; Myers C; Ferguson E; Zheng Y; Girard EJ; Przystal JM; Park G; Noll A; Pakiam F; Winter CA; Morris SM; Sarthy J; Cole BL; Leary SES; Crane C; Lieberman NAP; Mueller S; Nazarian J; Gottardo R; Brusniak MY; Mhyre AJ; Olson JM
Neuro Oncol; 2021 Mar; 23(3):376-386. PubMed ID: 33130903
[TBL] [Abstract][Full Text] [Related]
35. Bench-to-bedside investigations of H3 K27-altered diffuse midline glioma: drug targets and potential pharmacotherapies.
Rechberger JS; Bouchal SM; Power EA; Nonnenbroich LF; Nesvick CL; Daniels DJ
Expert Opin Ther Targets; 2023; 27(11):1071-1086. PubMed ID: 37897190
[TBL] [Abstract][Full Text] [Related]
36. STAT3 is a biologically relevant therapeutic target in H3K27M-mutant diffuse midline glioma.
Zhang L; Nesvick CL; Day CA; Choi J; Lu VM; Peterson T; Power EA; Anderson JB; Hamdan FH; Decker PA; Simons R; Welby JP; Siada R; Ge J; Kaptzan T; Johnsen SA; Hinchcliffe EH; Daniels DJ
Neuro Oncol; 2022 Oct; 24(10):1700-1711. PubMed ID: 35397475
[TBL] [Abstract][Full Text] [Related]
37. High frequency of H3 K27M mutations in adult midline gliomas.
Ebrahimi A; Skardelly M; Schuhmann MU; Ebinger M; Reuss D; Neumann M; Tabatabai G; Kohlhof-Meinecke P; Schittenhelm J
J Cancer Res Clin Oncol; 2019 Apr; 145(4):839-850. PubMed ID: 30610375
[TBL] [Abstract][Full Text] [Related]
38. Clinicoradiological characteristics of primary spinal cord H3 K27M-mutant diffuse midline glioma.
Cheng L; Wang L; Yao Q; Ma L; Duan W; Guan J; Zhang C; Wang K; Liu Z; Wang X; Wang Z; Wu H; Chen Z; Jian F
J Neurosurg Spine; 2022 Feb; 36(2):303-314. PubMed ID: 34560639
[TBL] [Abstract][Full Text] [Related]
39. A longitudinally extensive H3 K27M-mutant diffuse midline glioma in an elderly patient clinically mimicking central nervous system inflammation: a case report.
Babarczy K; Reisz Z; Szabo E; Rajda C; Vecsei L; Bodi I; Klivenyi P; Hortobagyi T; Szalardy L
Folia Neuropathol; 2020; 58(4):377-385. PubMed ID: 33480242
[TBL] [Abstract][Full Text] [Related]
40. Posterior fossa ependymoma H3 K27-mutant: an integrated radiological and histomolecular tumor analysis.
Mariet C; Castel D; Grill J; Saffroy R; Dangouloff-Ros V; Boddaert N; Llamas-Guttierrez F; Chappé C; Puget S; Hasty L; Chrétien F; Métais A; Varlet P; Tauziède-Espariat A
Acta Neuropathol Commun; 2022 Sep; 10(1):137. PubMed ID: 36104744
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
